Measles Virus Vaccine Live
drugOn this page
Also known as Measles vaccine (live)Measles vaccine liveMeasles virus live antigenaMeasles virus vaccineliveMeasleslive attenuatedMeasles-k
Summary
Measles Virus Vaccine Live (CHEMBL2109211) is a phase-3 clinical-stage vaccine component (ATC J07BD01); indicated across 2 conditions including meningococcal infection and measles.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Vaccine component
- ATC class: J07BD01
- Indications: 2 conditions
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109211 |
| Name | Measles Virus Vaccine Live |
| Type | Vaccine component |
| Max phase | 3 |
| ATC | J07BD01 |
Also known as: Measles vaccine (live), Measles vaccine live, Measles virus live antigen, a, Measles virus vaccine live, Measles virus vaccine, live, Measles, live attenuated, Measles-k, MEASLES VIRUS VACCINE LIVE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| meningococcal infection | 3 | MONDO:0005373 | EFO:0004249 |
| measles | 2 | MONDO:0004619 | EFO:1002025 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: meningococcal infection